Targeting p53 Cancer Therapy Market Trends and Forecast
The future of the global targeting p53 cancer therapy market looks promising with opportunities in the hospital and clinic markets. The global targeting p53 cancer therapy market is expected to grow with a CAGR of 15.1% from 2025 to 2031. The major drivers for this market are the increasing cancer prevalence, the advancements in genetic research, and the growing investment in personalized medicine.
• Lucintel forecasts that, within the type category, immunotherapy is expected to witness the highest growth over the forecast period due to immunotherapy offers durable responses, targets cancer more precisely.
• Within the application category, hospital is expected to witness the higher growth due to hospitals provide comprehensive care, including emergency services & specialized treatments.
• In terms of region, North America is expected to witness the highest growth over the forecast period.
Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below.
Emerging Trends in the Targeting p53 Cancer Therapy Market
The targeting p53 cancer therapy market is experiencing a profound transformation, moving beyond the historical challenges of drugging p53 to embrace innovative and diverse strategies. These emerging trends reflect a deeper understanding of p53 biology, advanced technological capabilities, and a commitment to precision oncology. The multifaceted nature of p53 dysfunction, encompassing both loss of tumor suppression and gain-of-function properties, is driving a variety of therapeutic approaches. This evolution promises to open new avenues for treating a large proportion of human cancers that harbor p53 alterations.
• Reactivation of Mutant p53: A leading trend is the development of small molecules that can reactivate mutant p53, restoring its tumor suppressor function. Many p53 mutations are missense mutations that lead to misfolded proteins. Compounds like APR-246 (eprenetapopt) aim to bind to and stabilize these misfolded mutant p53 proteins, enabling them to regain their proper structure and activity. This approach is highly promising as it directly targets the mutated protein that often contributes to cancer progression and drug resistance, effectively turning an oncogene back into a tumor suppressor.
• Degradation of Mutant p53: Another significant trend focuses on selectively degrading mutant p53 proteins. Accumulation of mutant p53 often confers gain-of-function properties, promoting tumor growth and metastasis. Strategies involve using proteasome inhibitors or developing specific degraders that target mutant p53 for destruction via the ubiquitin-proteasome system. This approach aims to eliminate the oncogenic effects of mutant p53, thereby sensitizing cancer cells to conventional therapies or inducing cell death. This direct removal of the harmful protein offers a potent therapeutic avenue.
• Targeting the p53-MDM2/MDM4 Pathway : For cancers that retain wild-type p53 but have its activity suppressed, often due to overexpression of negative regulators like MDM2 or MDM4, targeting the p53-MDM2/MDM4 interaction is a crucial trend. Small molecule inhibitors (e.g., Nutlins, MI-77301) prevent MDM2 from binding to and degrading p53, thereby stabilizing and reactivating endogenous wild-type p53. This approach is particularly relevant for leukemias and sarcomas that frequently harbor wild-type p53 but exhibit MDM2 overexpression, offering a pathway to unleash p53ÄX%$%Xs natural tumor-suppressive functions.
• Synthetic Lethality Approaches with p53 Status: The concept of synthetic lethality, where inhibition of two genes or pathways is lethal only when both are compromised, is an emerging trend in p53-targeted therapy. Researchers are identifying vulnerabilities that arise specifically in p53-deficient cancer cells that are not present in wild-type p53 cells. For example, some DNA damage response pathways become essential when p53 is absent. Targeting these pathways could selectively kill cancer cells while sparing healthy cells, providing a highly specific and potentially less toxic therapeutic strategy.
• Gene Therapy and Oncolytic Viruses: Gene therapy, involving the introduction of wild-type TP53 genes into cancer cells, and oncolytic viruses, engineered to selectively replicate in and lyse cancer cells often due to p53 pathway defects, represent ongoing trends. These approaches aim to restore p53 function or exploit its absence to induce tumor cell death. Recent advancements focus on improving delivery systems and enhancing tumor specificity, as well as combining them with other therapeutic modalities like immunotherapy to achieve more robust and durable anti-tumor responses.
These emerging trends are profoundly reshaping the targeting p53 cancer therapy market by offering diverse and sophisticated strategies to address p53 dysfunction. The shift towards directly reactivating or degrading mutant p53, unleashing wild-type p53 activity, exploiting synthetic lethal vulnerabilities, and refining gene and viral therapies is transforming the landscape. This multifaceted approach is moving the field closer to effective and personalized treatments for the vast number of cancers affected by p53 alterations.
Recent Development in the Targeting p53 Cancer Therapy Market
The targeting p53 cancer therapy market is experiencing a period of significant innovation, driven by decades of research into the "guardian of the genome." Historically, p53 was considered an "undruggable" target, but recent breakthroughs in molecular biology and drug discovery have opened new avenues. These developments reflect a global effort to develop effective treatments for the large proportion of human cancers that harbor p53 mutations or dysregulation, offering hope for improved patient outcomes. The focus is increasingly on precision and specificity in targeting this crucial tumor suppressor pathway.
• Advancements in Mutant p53 Reactivators: A key development is the progress in small molecule compounds that can reactivate misfolded mutant p53 proteins. For example, compounds like APR-246 (eprenetapopt) have shown promise in clinical trials, aiming to restore wild-type p53 conformation and function in tumors with specific p53 mutations. This directly addresses the oncogenic effects of mutant p53, leading to tumor cell apoptosis or cell cycle arrest. The impact is a paradigm shift, enabling the "drugging" of previously intractable p53 mutations and potentially sensitizing these resistant cancers to existing therapies.
• Development of MDM2/MDM4 Inhibitors for Wild-Type p53 Tumors: Another significant development involves the continued refinement and clinical testing of MDM2 and MDM4 inhibitors. These small molecules prevent the degradation of wild-type p53 by its negative regulators, thereby increasing p53 levels and restoring its tumor-suppressive activity. This approach is particularly impactful for cancers that retain functional p53 but have elevated MDM2/MDM4, such as certain sarcomas and leukemias. It offers a targeted strategy to unleash the endogenous tumor suppressor pathway without genetic manipulation.
• Gene Therapy and Oncolytic Viruses Enhancements: Recent advancements in gene therapy and oncolytic virotherapy for p53 include improved delivery systems and enhanced tumor specificity. Researchers are developing new viral vectors (e.g., adenoviruses, adeno-associated viruses) to deliver wild-type TP53 genes more efficiently to cancer cells. Additionally, oncolytic viruses are being engineered to selectively replicate in and lyse p53-deficient tumor cells, while sparing healthy cells. The impact is a more precise and potent approach to directly restoring p53 function or exploiting p53 deficiencies for therapeutic gain, often in combination with other agents.
• Exploration of Synthetic Lethality Strategies: The concept of synthetic lethality is gaining traction, where a genetic vulnerability introduced by p53 loss can be exploited. Recent developments involve identifying specific pathways that become essential for cancer cell survival only in the absence of functional p53. Drugs targeting these pathways (e.g., certain DNA damage response inhibitors) can selectively kill p53-mutant cancer cells while sparing normal cells. This provides a highly specific therapeutic window, offering a promising strategy for cancers where direct p53 restoration remains challenging.
• Combination Therapies Integrating p53 Modulators: There is a growing trend towards combining p53-targeting agents with conventional chemotherapy, radiation, or immunotherapy. Preclinical and early clinical studies are exploring how reactivating or modulating p53 can sensitize resistant tumors to existing treatments or enhance immune responses. For example, p53 restoration can induce immunogenic cell death. The impact is a synergistic approach, potentially leading to deeper and more durable responses, addressing the challenge of drug resistance and improving overall patient survival by leveraging multiple anti-cancer mechanisms.
These recent developments are profoundly impacting the targeting p53 cancer therapy market by offering a diverse arsenal of therapeutic strategies. The progress in mutant p53 reactivation, MDM2/MDM4 inhibition, advanced gene therapies, synthetic lethality approaches, and strategic combination regimens is transforming the treatment landscape for a vast array of cancers. This multifaceted innovation provides renewed optimism for developing highly effective and personalized treatments that address one of the most fundamental drivers of cancer.
Strategic Growth Opportunities in the Targeting p53 Cancer Therapy Market
The targeting p53 cancer therapy market is ripe with strategic growth opportunities, driven by the pervasive role of p53 in carcinogenesis and the increasing sophistication of therapeutic interventions. These opportunities span various applications within cancer treatment, from specific cancer types to combination therapies and diagnostic integration. Leveraging a deeper understanding of p53 biology and novel drug delivery platforms will be key to unlocking these opportunities. Companies that can effectively address the complexities of p53 dysfunction across different cancer settings are poised for significant market expansion and impact.
• Developing Specific Therapies for p53 Hotspot Mutations: A significant strategic growth opportunity lies in developing highly specific small molecules or peptides that target the most prevalent p53 hotspot mutations (e.g., R175H, R248Q, R273H). These mutations often lead to gain-of-function properties that actively promote cancer. Creating therapies that can precisely reactivate the wild-type conformation of these specific mutant p53 proteins or induce their degradation offers a high-value, precision oncology approach. This addresses a large subset of p53-mutated cancers with tailored interventions, maximizing therapeutic efficacy and minimizing off-target effects.
• Combining p53-Targeting Agents with Immunotherapy: Integrating p53-targeting therapies with immunotherapy represents a major growth opportunity. p53 dysfunction can contribute to an immunosuppressive tumor microenvironment. Restoring p53 function or degrading mutant p53 could potentially "sensitize" tumors to immune checkpoint inhibitors or other immunotherapies. Developing strategic combination regimens that enhance anti-tumor immune responses through p53 modulation offers a powerful approach for a broader range of cancers, including those historically resistant to immunotherapy. This synergistic strategy can lead to more durable and complete responses.
• Expanding Applications in Solid Tumors with High p53 Mutation Rates: While initial p53-targeted therapies may focus on certain hematological malignancies or sarcomas, there is a substantial opportunity to expand their application to common solid tumors with high p53 mutation rates, such as lung, colorectal, ovarian, and breast cancers. This requires demonstrating efficacy and safety in diverse tumor microenvironments and addressing tumor heterogeneity. Successful clinical trials in these large patient populations would significantly broaden the market reach, providing critical solutions for some of the most challenging cancers.
• Integrating Biomarker-Driven Patient Selection and Monitoring: Developing robust companion diagnostics for patient stratification and therapeutic monitoring is a crucial growth opportunity. Identifying which specific p53 mutation or pathway dysregulation a patient has is essential for selecting the most appropriate p53-targeted therapy. Furthermore, liquid biopsies and other non-invasive methods for monitoring treatment response and detecting resistance mutations can guide therapy adjustments. This biomarker-driven approach ensures that the right patients receive the right treatment, optimizing clinical outcomes and resource utilization.
• Leveraging Gene Therapy and Oncolytic Viruses for Difficult-to-Treat Cancers: For highly aggressive or recurrent cancers where conventional treatments are limited, gene therapy delivering wild-type p53 or oncolytic viruses engineered to selectively target p53-deficient cells offer a strategic growth avenue. Developing advanced delivery systems (e.g., tumor-specific vectors, nanoparticle delivery) to enhance efficacy and reduce systemic toxicity is key. Focusing on niche, high-need indications, such as glioblastoma or pancreatic cancer, where p53 mutations are frequent and prognosis is poor, could establish a strong market presence and provide breakthrough solutions.
These strategic growth opportunities are profoundly impacting the targeting p53 cancer therapy market by driving innovation towards more precise, effective, and broadly applicable treatments. The focus on targeting specific p53 mutations, combining with immunotherapy, expanding into major solid tumors, integrating advanced diagnostics, and leveraging gene/viral therapies is transforming the approach to cancer care. By capitalizing on these opportunities, companies can not only achieve significant market growth but also redefine the treatment landscape for a vast proportion of cancer patients.
Targeting p53 Cancer Therapy Market Driver and Challenges
The targeting p53 cancer therapy market is at a pivotal juncture, influenced by a complex interplay of scientific breakthroughs, economic pressures, and regulatory considerations. Its trajectory is defined by compelling drivers that underscore the critical need for effective p53-modulating agents, alongside significant challenges that necessitate persistent innovation and strategic navigation. Understanding these dynamics is essential for market players to effectively develop and commercialize therapies that address one of the most fundamental aspects of cancer biology.
The factors responsible for driving the targeting p53 cancer therapy market include:
1. High Frequency of TP53 Mutations in Human Cancers: The most significant driver is the remarkably high frequency of TP53 gene mutations, occurring in over 50% of all human cancers, including major types like lung, colorectal, and ovarian cancers. This makes p53 dysfunction a universal feature across oncology, representing a vast patient population in need of effective treatments. The widespread involvement of p53 in cancer progression underscores the immense therapeutic potential and the urgent clinical demand for therapies that can restore its function or mitigate the effects of its mutation.
2. Growing Understanding of p53 Biology and Dysfunction: Decades of intensive research have led to a profound understanding of p53ÄX%$%Xs diverse roles in tumor suppression (e.g., apoptosis, cell cycle arrest, DNA repair) and the complex mechanisms by which its function is lost or altered in cancer. This deeper biological insight, including the identification of gain-of-function properties of mutant p53, provides actionable targets for drug discovery. The continuous elucidation of p53 pathways fuels the development of more precise and effective therapeutic strategies.
3. Advancements in Drug Discovery Technologies: Breakthroughs in medicinal chemistry, structural biology, high-throughput screening, and computational drug design have revolutionized the ability to discover and optimize molecules that target p53. These technologies enable the identification of compounds that can reactivate misfolded mutant p53, inhibit its negative regulators like MDM2/MDM4, or induce its degradation. The availability of sophisticated tools accelerates the translation of basic scientific discoveries into viable drug candidates, driving the market forward.
4. Unmet Medical Needs for p53-Mutated Cancers: Cancers with TP53 mutations are often associated with aggressive disease, poor prognosis, and resistance to conventional chemotherapy and radiation. This creates a significant unmet medical need for effective therapeutic options. The promise of p53-targeted therapies to overcome this resistance and improve outcomes for these challenging cancers is a powerful driver for research, development, and investment in this market segment, offering hope to patients with limited current options.
5. Increasing Investment in Precision Oncology: The global shift towards precision oncology, which aims to tailor treatments based on a tumorÄX%$%Xs molecular profile, is a strong driver. As molecular profiling becomes more routine, the identification of p53 mutations guides therapeutic decisions. This focus on personalized medicine encourages investment in drugs that target specific genetic alterations like p53 mutations, creating a favorable environment for the development and commercialization of p53-targeted therapies that can address the specific drivers of an individualÄX%$%Xs cancer.
Challenges in the targeting p53 cancer therapy market are:
1. Complexity and Heterogeneity of p53 Mutations: The sheer number and diversity of TP53 mutations (over 2,500 different point mutations alone, plus deletions and insertions) present a formidable challenge. Each mutation can lead to different functional consequences, making it difficult to develop broadly effective therapies. Some mutant p53 proteins acquire gain-of-function properties that are distinct from the loss of wild-type function, requiring different therapeutic strategies. This heterogeneity necessitates highly specific approaches, which can be costly and time-consuming to develop.
2. Toxicity and Off-Target Effects of p53 Activation: Reactivating p53 in cancer cells also carries the risk of activating it in healthy cells, leading to potential off-target toxicities. Wild-type p53 plays crucial roles in normal cellular processes, and its sustained activation could lead to adverse effects in rapidly proliferating normal tissues like bone marrow and gastrointestinal lining. Balancing therapeutic efficacy in cancer cells with minimal toxicity to normal cells is a significant hurdle, requiring highly selective compounds or targeted delivery mechanisms.
3. Delivery Challenges for Gene-Based Therapies: For gene therapy approaches aimed at restoring wild-type p53, effective and safe delivery of the therapeutic gene to tumor cells remains a major challenge. Viral vectors can elicit immune responses or have limited tumor specificity. Non-viral delivery methods often suffer from low efficiency. Overcoming these delivery hurdles, ensuring efficient tumor transduction without systemic toxicity, is critical for the clinical success and widespread adoption of p53 gene therapies, adding complexity and cost to their development.
In conclusion, the targeting p53 cancer therapy market is experiencing significant momentum driven by the high prevalence of p53 mutations, a deepening understanding of its complex biology, and advancements in drug discovery technologies. The urgent unmet medical needs in p53-mutated cancers and the broader shift towards precision oncology further propel innovation. However, the market faces substantial challenges, including the vast heterogeneity of p53 mutations, the critical need to balance therapeutic efficacy with managing potential toxicity in healthy cells, and the ongoing complexities of gene-based therapy delivery. Addressing these multifaceted challenges through sustained research, refined drug development, and strategic partnerships will be pivotal for realizing the full transformative potential of p53-targeted therapies in cancer treatment.
List of Targeting p53 Cancer Therapy Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies targeting p53 cancer therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the targeting p53 cancer therapy companies profiled in this report include-
• Sibiono GeneTech
• Kartos Therapeutics
• SynerGene Therapeutics
• MultiVir
• Rain Oncology
• Alieron Therapeutics
• Aprea Therapeutics
Targeting p53 Cancer Therapy Market by Segment
The study includes a forecast for the global targeting p53 cancer therapy market by type, application, and region.
Targeting p53 Cancer Therapy Market by Type [Value from 2019 to 2031]:
• Small Molecule Drugs
• Immunotherapy
• Gene Therapy
• Others
Targeting p53 Cancer Therapy Market by Application [Value from 2019 to 2031]:
• Hospital
• Clinic
• Others
Targeting p53 Cancer Therapy Market by Region [Value from 2019 to 2031]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
Country Wise Outlook for the Targeting p53 Cancer Therapy Market
Targeting p53 in cancer therapy represents a critically important and intensely researched field, given that mutations in the TP53 gene, which encodes the p53 tumor suppressor protein, occur in over 50% of all human cancers. These mutations often lead to loss of p53ÄX%$%Xs protective functions and, in many cases, acquire new oncogenic properties. Developments in this market are focused on restoring wild-type p53 function, degrading mutant p53, or exploiting vulnerabilities created by p53 loss. This area holds immense promise for developing highly effective, personalized cancer treatments, moving beyond conventional therapies to address one of cancerÄX%$%Xs most fundamental drivers.
• United States: In the United States, the targeting p53 cancer therapy market is characterized by a robust pipeline of novel small molecules and gene therapies. Significant progress has been made in developing MDM2 inhibitors, which aim to activate wild-type p53 in tumors where its degradation is accelerated. Clinical trials are actively testing compounds that reactivate mutant p53 or induce its degradation. There is also a strong emphasis on understanding the diverse gain-of-function properties of mutant p53 to develop therapies that specifically target these oncogenic activities. Collaborations between academia, biotech, and large pharmaceutical companies are accelerating drug discovery and clinical translation.
• China: China has been a pioneer in p53-targeted gene therapy, notably with the approval of Gendicine, an adenoviral vector delivering wild-type p53, for head and neck cancer. This demonstrates ChinaÄX%$%Xs commitment to gene-based interventions. Recent developments also include active research into small molecules that reactivate or degrade mutant p53, often leveraging traditional Chinese medicine compounds or novel chemical entities. There is a growing focus on combining p53-targeting agents with conventional chemotherapy or radiation, and significant investment in understanding the mechanisms of p53 dysfunction in various prevalent Chinese cancer types to develop localized solutions.
• Germany: GermanyÄX%$%Xs approach to targeting p53 cancer therapy is rooted in strong academic research and preclinical development. Renowned for its structural biology expertise, Germany has contributed significantly to understanding p53 protein dynamics and designing molecules that can restore its wild-type conformation, particularly for specific hotspot mutations. While clinical trials for p53-targeting agents are ongoing, the emphasis is often on rigorous mechanistic studies and combination therapies. Researchers are exploring how p53 modulation can enhance the efficacy of immunotherapy and conventional treatments, leveraging GermanyÄX%$%Xs advanced biomedical research infrastructure.
• India: IndiaÄX%$%Xs market for targeting p53 cancer therapy is in an earlier but rapidly growing phase, driven by increasing cancer burden and a growing research ecosystem. While access to highly specialized therapies remains a challenge, there is rising interest in research on small molecules that can modulate p53 pathways, including those inspired by traditional medicine. Academic institutions are engaging in preclinical studies to identify novel compounds and understand the genetic landscape of p53 mutations in the Indian population. The focus is on developing affordable and accessible therapeutic strategies, potentially through drug repurposing or local development of p53 pathway modulators.
• Japan: JapanÄX%$%Xs p53 cancer therapy market is highly advanced, with a strong emphasis on innovative approaches, particularly in gene therapy and oncolytic viruses. Japanese researchers have been at the forefront of exploring oncolytic viruses engineered to replicate preferentially in p53-deficient cancer cells, offering a unique therapeutic modality. There is also significant research into small molecules that can restore wild-type p53 function or induce the degradation of mutant p53. JapanÄX%$%Xs strong biomedical research base and technological capabilities support the development of sophisticated p53-targeting strategies, often focusing on combination therapies to maximize efficacy.
Features of the Global Targeting p53 Cancer Therapy Market
Market Size Estimates: Targeting p53 cancer therapy market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
Segmentation Analysis: Targeting p53 cancer therapy market size by types, applications, and region in terms of value ($B).
Regional Analysis: Targeting p53 cancer therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, application, and regions for the targeting p53 cancer therapy market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the targeting p53 cancer therapy market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the growth forecast for targeting p53 cancer therapy market?
Answer: The global targeting p53 cancer therapy market is expected to grow with a CAGR of 15.1% from 2025 to 2031.
Q2. What are the major drivers influencing the growth of the targeting p53 cancer therapy market?
Answer: The major drivers for this market are the increasing cancer prevalence, the advancements in genetic research, and the growing investment in personalized medicine.
Q3. What are the major segments for targeting p53 cancer therapy market?
Answer: The future of the targeting p53 cancer therapy market looks promising with opportunities in the hospital and clinic markets.
Q4. Who are the key targeting p53 cancer therapy market companies?
Answer: Some of the key targeting p53 cancer therapy companies are as follows:
• Sibiono GeneTech
• Kartos Therapeutics
• SynerGene Therapeutics
• MultiVir
• Rain Oncology
• Alieron Therapeutics
• Aprea Therapeutics
Q5. Which targeting p53 cancer therapy market segment will be the largest in future?
Answer: Lucintel forecasts that immunotherapy is expected to witness the highest growth over the forecast period due to immunotherapy offers durable responses, targets cancer more precisely.
Q6. In targeting p53 cancer therapy market, which region is expected to be the largest in next 5 years?
Answer: North America is expected to witness the highest growth over the forecast period.
Q7. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the targeting p53 cancer therapy market by type (small molecule drugs, immunotherapy, gene therapy, and others), application (hospital, clinic, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Targeting p53 Cancer Therapy Market, Targeting p53 Cancer Therapy Market Size, Targeting p53 Cancer Therapy Market Growth, Targeting p53 Cancer Therapy Market Analysis, Targeting p53 Cancer Therapy Market Report, Targeting p53 Cancer Therapy Market Share, Targeting p53 Cancer Therapy Market Trends, Targeting p53 Cancer Therapy Market Forecast, Targeting p53 Cancer Therapy Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.